New drug promising for melanoma

NEW YORK (Reuters Health) - In an early-stage trial involving patients with melanoma that had spread to other sites in the body, a biological drug dubbed ipilimumab was generally well tolerated and showed signs of attacking the malignancy, researchers report.

“Ipilimumab can induce both clinically relevant responses and long-term stable disease,” lead investigator Dr. Jeffrey Weber told Reuters Health.

As reported in the Journal of Clinical Oncology, Weber, at the H. Lee Moffitt Cancer Center in Tampa, Florida, and colleagues studied 88 patients with unresectable metastatic melanoma.

They were given either a single high dose of ipilimumab, or multiple low doses, or multiple medium doses.

Although a maximum-tolerated dose was not reached in the first two groups, 6 of the 23 patients given multiple medium doses showed toxic side effects that limited the amount that could be given.

However, one patient in this group had a complete response, one had a partial response and seven had stable disease, giving a disease control rate of 39 percent.

Durable responses were seen in all of the groups, say the investigators, and they conclude that the multiple medium-dose regimen provided the best results.

“Ipilimumab is an active drug in metastatic melanoma,” Weber concluded.

Overall survival in more recent studies, aggregating over 300 patients, “suggests that median survival for mostly untreated first-line patients is in excess of 13 months, which is quite favorable,” he added.

SOURCE: Journal of Clinical Oncology, November 17, 2008.


Related Posts:

LONDON (Reuters) - Giving just one fifth the dose of a commonly used meningitis vaccine may be as effective as using the full dose, researchers said on Tuesday. The finding should allow medics to stretch scarce vaccine resources, especially during epidemics in Africa. A clinical study conducted in Uganda by Epicentre — the research arm of medical

Full Post: Partial vaccine dose may work as well as full shot

By Toni Clarke BOSTON (Reuters) - Biotechnology company Antigenics Inc said on Monday that its Oncophage vaccine extended survival in a small study of patients with brain cancer. Results from the 12-patient study, which were presented at the annual meeting of the Society for Neuro-Oncology in Las Vegas, showed that patients who were vaccinated with Oncophage following

Full Post: Antigenics vaccine promising in small cancer study

WASHINGTON (Reuters) - Regular mobile phone use does not appear to increase a person’s risk of getting a type of cancer called melanoma of the eye, German researchers said on Tuesday. The study involving about 1,600 people detected no link between the time a person spent using a cell phone over about a decade and their

Full Post: Study sees no eye cancer risk from mobile phones

NEW YORK (Reuters Health) - Research from Italy provides new evidence that exposure to the industrial solvent benzene increases a person’s risk of developing multiple myeloma. Dr. Adele Seniori Constantini of the Center for Study and Prevention of Cancer and her colleagues also found an increased risk of chronic lymphoid leukemia with benzene exposure. Two other

Full Post: New study backs solvent, leukemia link

WASHINGTON (Reuters) - Adding radiation therapy to standard drug treatment can cut in half the death rate from advanced prostate cancer and should become the standard of care globally, Swedish researchers reported on Monday. Their study of more than 800 prostate cancer patients showed that nearly 24 percent of men who got only standard drugs had

Full Post: Radiation therapy cuts prostate cancer death: study

Site Navigation

Most Read